Is time to biochemical failure a good surrogate endpoint for overall survival?

For many years researchers have been trying to identify so-called “surrogate” endpoints that can be used to predict overall and prostate cancer-specific survival with high accuracy. … READ MORE …

MFS as an endpoint in clinical trials

Earlier this year, two drugs (apalutamide/Erleada and enzalutamide/Xtandi) were each approved for the treatment of non-metastatic, castration-resistant prostate cancer (nmCRPC) based on the use of metastasis-free survival (MFS) as the study endpoint in clinical trials. … READ MORE …

CTC levels as a surrogate endpoint for clinical trials in mCRPC

A newly published analysis of data from five major clinical trials involving > 6,000 patients has provided us with additional information about circulating tumor cell (CTC) levels as an endpoint for clinical trials. … READ MORE …

Nadir PSA predicts survival after radiation and androgen deprivation for unfavorable risk patients

The following commentary addresses the article on risk for recurrent prostate cancer that we had mentioned briefly yesterday.

If a treatment isn’t working, we want to know as quickly as possible so we can try a salvage therapy while it can still make a difference. … READ MORE …

Is overall survival a useful endpoint for evaluating therapies for intermediate-risk patients?

In a recent commentary, we looked at the utility of surrogate endpoints in evaluating therapies. … READ MORE …

So … what IS going to be “hot” at ASCO this year?

It appears that when it comes to the new data to be presented at ASCO this year, this will be the first time for several years that we don’t see some really groundbreaking new data from a large Phase III trial of some new form of therapy at one of the major meetings. But there is a lot of detail and a lot of information about new trials in development. … READ MORE …

Can the “bone scan index” act as a surrogate marker for survival?

One of the problems with clinical trials for late-stage prostate cancer today is that we commonly need to follow all patients until death before we can collect sufficiently accurate data to be certain that a particular product is or is not effective in extending patient survival. … READ MORE …